Clinical Implications of Isocitrate Dehydrogenase Mutations and Targeted Treatment of Acute Myeloid Leukemia with Mutant Isocitrate Dehydrogenase Inhibitors-Recent Advances, Challenges and Future Prospects.

Abstract excerpt

Despite the better understanding of the molecular mechanisms contributing to the pathogenesis of acute myeloid leukemia (AML) and improved patient survival in recent years, AML therapy still remains a clinical challenge. For this reason, it is important to search for new therapies that will enable the achievement of remission. Recently, the Food and Drug Administration approved three mutant IDH (mIDH) inhibitors...

Topics

Join the communities discussing this publication.

• Antineoplastic Agents
• Drug Resistance, Neoplasm
• Enzyme Inhibitors
• Isocitrate Dehydrogenase
• Leukemia, Myeloid, Acute